前列腺癌5×9 Gy立体定向放疗尿道保留的剂量学可行性
本研究基于20例前列腺癌患者的剂量学CT与MRI融合图像,评估在尿道剂量限制为5×7.25 Gy的前提下,将前列腺靶区剂量提升至5×9 Gy的可行性。结果显示所有患者尿道剂量均在耐受范围内,肿瘤靶区覆盖良好,除直肠V36Gy≤1cc外,危及器官剂量均满足要求。该方案将为后续III期随机试验奠定基础。
要点
- 前列腺SBRT剂量提升至5×9 Gy时,尿道+2mm区域限制在5×7.25 Gy是可行的。
- 肿瘤靶区覆盖未受影响,PTVt剂量达44.6 Gy(41.2-45.9)。
- 除直肠V36Gy≤1cc外,其余危及器官剂量均符合限制。
局限性
- 本研究为剂量学可行性研究,样本量较小(20例),尚未报告临床结局。
- 除直肠V36Gy≤1cc外,其他危及器官剂量均满足限制,但直肠剂量限制略有违反。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: The most commonly used dose for prostate cancer stereotactic body radiotherapy (SBRT) is 5 × 7.25 Gy. The aim of this study was to evaluate the dosimetric feasibility of a 5 × 9 Gy SBRT regimen while still limiting the dose to the urethra to 5 × 7.25 Gy. This dosimetric study is part of the groundwork for a future Phase III randomized trial.
METHODS: The prostate, the urethra and the tumors were delineated on 20 dosimetric CT-scans with MRI-registration. The planning target volume (PTVp) was defined as a 5 mm expansion (3 mm posteriorly) of the prostate. The planning at risk volume (PRVu) was defined as a 2 mm expansion of the urethra. The tumors were delineated on the MRI (GTVt) and a 3 mm-margin was added to create a tumoral planning target volume (PTVt). IMRT plans were optimized to deliver 5 × 9 Gy to the PTVp, limiting the dose to the PRVu to 5 × 7.25 Gy. Results are presented using average (range) values.
RESULTS: PTVp doses were D98% = 36.2 Gy (35.6-36.8), D2% = 46.9 Gy (46.5-47.5) and mean dose = 44.1 Gy (43.8-44.5). The dose to the PRVu was within tolerance limits for all 20 patients: V34.4Gy = 99.8% (99.2-100) and D5% = 38.7 Gy (38.6-38.8). Dose coverage of PTV-PRVu was D95% = 40.6 Gy (40.5-40.9), D5% = 46.6 Gy (46.2-47.2) and mean dose = 44.6 Gy (44.3-44.9). Dose to the PTVt reached 44.6 Gy (41.2-45.9). Doses to the OAR were respected, except V36Gy ≤1 cc for the rectum.
CONCLUSION: A SBRT dose-escalation to 5 × 9 Gy on the prostate while sparing the urethra + 2 mm at 36.25 Gy is feasible without compromising dose coverage to the tumor. This radiation regimen will be used for a Phase-III trial.
ADVANCES IN KNOWLEDGE: In prostate SBRT, dose optimization on the urethra is feasible and could decrease urinary toxicities.
引用
- Benhmida S, Beneux A, Udrescu C, et al. Dosimetric feasibility of stereotactic irradiation of primary prostate cancer at 5x9 Gy with a method of urethral sparing. Br J Radiol. 2021. PMID: 34283647. doi:10.1259/bjr.20210142
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。